Life Science Software Market Report 2026

The life science software market size has grown rapidly in recent years. It will grow from $20.07 billion in 2025 to $22.29 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to growth in life science research activities, increasing complexity of clinical trials, rising adoption of digital record keeping, expansion of pharmaceutical and biotech industries, early implementation of enterprise software solutions.

The life science software market size is expected to see rapid growth in the next few years. It will grow to $34.45 billion in 2030 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to rising demand for scalable software solutions, increasing focus on operational efficiency, growth in global clinical trial volumes, expanding use of software in pharmacovigilance, higher investments in life science digital infrastructure. Major trends in the forecast period include increasing adoption of integrated life science platforms, rising demand for workflow automation in research processes, growing focus on regulatory and compliance software, expansion of software usage across clinical and preclinical activities, increasing need for data standardization and interoperability.

The increasing demand for personalized medicine is expected to drive the growth of life science software in the coming years. Personalized medicine is a healthcare approach that customizes medical decisions and treatments based on individual characteristics, including genetics, lifestyle, and environmental factors. Advanced software solutions are essential for personalized medicine to standardize and integrate data from multiple sources, such as wearable devices, genetic tests, and electronic health records. Life science software is crucial in enabling the analysis and interpretation of complex biological data, allowing researchers and healthcare professionals to develop treatment plans tailored to individual patient profiles. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, compared to 6 approvals in 2022. Consequently, the growing demand for personalized medicine is fueling the expansion of the life science software market.

Major companies operating in the life science software market are adopting advanced technologies, such as generative AI, machine learning (ML), and computer-aided drug design (CADD), to improve the drug discovery process, enhance efficiency, and accelerate breakthroughs. Generative AI is used to create novel molecular structures, while ML algorithms process vast datasets to identify potential drug candidates and predict their effectiveness. When combined with CADD tools, these technologies allow researchers to computationally simulate and optimize drug interactions, significantly streamlining the identification and development of promising compounds. For example, in December 2023, Merck, a Germany-based science and technology company, launched AIDDISON, a drug discovery software. AIDDISON is designed to accelerate the identification of novel medications and improve the efficiency of the drug development process. The platform leverages artificial intelligence (AI) and machine learning (ML) technologies, enabling it to analyze massive volumes of data and identify potential medication candidates faster and more effectively than traditional methods.

In August 2024, Valsoft Corporation Inc., a Canada-based company specializing in the acquisition and development of vertical market software businesses, acquired Anju Software for an undisclosed amount. This acquisition is intended to expand Valsoft's presence in the life sciences sector and strengthen its portfolio with flexible solutions for clinical research, medical affairs, and data science. Anju Software is a US-based company that develops and designs life sciences software platforms.

Major companies operating in the life science software market are International Business Machines Corp, Oracle, SAP, Dassault Systèmes, SAS Institute Inc, Veeva Systems Inc, Medidata Solutions Inc, ArisGlobal LLC, Perceptive Informatics Inc, Cegedim SA, Model N Inc, TIBCO Software Inc, Epic Systems Corporation, MEDITECH, Allscripts Healthcare LLC, CPSI, Thermo Fisher Scientific Inc, PAREXEL International Corporation, Optum Inc, Cognizant, DXC Technology Co, HCL Technologies Ltd.

North America was the largest region in the life science software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the life science software market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the life science software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the life science software market by increasing costs related to imported IT infrastructure, licensed software components, and implementation services. These impacts are more evident in on-premise deployment models and R&D and compliance applications, particularly in regions such as Asia-Pacific and Europe that rely on cross-border technology sourcing. Healthcare institutes and biopharmaceutical companies face higher deployment and maintenance expenses due to tariff pressures. At the same time, tariffs have supported local software development, encouraged hosted deployment adoption, and strengthened regional software ecosystems, contributing to long-term market stability.

The life science software market research report is one of a series of new reports that provides life science software market statistics, including life science software industry global market size, regional shares, competitors with a life science software market share, detailed life science software market segments, market trends and opportunities, and any further data you may need to thrive in the life science software industry. This life science software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Life science software encompasses specialized applications and platforms developed to support and optimize a wide range of processes within the life sciences sector. It is employed across multiple areas of the industry to advance research, streamline workflows, and enhance overall efficiency.

The primary categories of life science software include predictive, descriptive, and prescriptive. Predictive software leverages predictive analytics, is available in both on-premise and hosted formats, and finds applications in areas such as marketing, compliance, research and development, pharmacovigilance, and supply chain management. It is used by various end users, including healthcare institutions, the biopharmaceutical industry, the medical devices sector, and medical research centers.

The life science software market includes revenues earned by entities by providing services such as genomic analysis services, clinical trial management services, laboratory information management system (LIMS) services, bioinformatics and computational biology services, drug discovery and development services, and regulatory compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The Life Science Software market consists of sales of laboratory information management systems, electronic lab notebooks, scientific data analysis and visualization software, and scientific modeling and simulation software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.